DOI: 10.36347/sjams.2018.v06i07.016

Pages: 2691-2696

To identify the role of Ischemia Modified Albumin (IMA) as a cardiac biomarker in the early diagnosis of Acute Coronary Syndrome (ACS). A study was done including 40 Acute Coronary Syndrome patients (Group 2) and 40 age sex matched controls (Group 1). Blood samples were estimated for Ischemia Modified Albumin, Troponin T, CK-MB, glucose, urea, creatinine and albumin. Stastical analysis was done using SPSS version 16. Serum IMA levels and CK-MB levels were significantly increased in ACS patients when compared to the controls and they were positively correlated. No significant difference was observed in serum Albumin levels among the groups. Sensitivity of IMA was increased when used in combination with other markers like CK-MB and cTnT in the diagnosis of ACS. From our study, Ischemia Modified Albumin is a sensitive cardiac biomarker to detect myocardial ischemia and is more helpful in identifying patients with unstable angina when compared to other routine biomarkers. The serum levels of IMA and CK-MB are significantly elevated in ACS patients, when compared to the healthy controls. The combination of these markers had better sensitivity in identifying patients with ACS. Cardiovascular diseases are the leading causes of morbidity and mortality. Newer technologies have been developed in the past few decades to monitor cardiovascular disease more efficiently.